CDKN2A

(redirected from CDKN2)
Also found in: Acronyms.

CDKN2A

A gene on chromosome 9p21 that encodes an alternate open reading frame (ARF) product, which acts as a tumour suppressor by binding to MDM2 and blocking its nucleocytoplasmic shuttling by sequestering it in the nucleolus. This inhibits MDM2’s oncogenic activity, which would normally degrade p53, a tumour suppressor protein. CDKN2A also induces G2 arrest and apoptosis, independent of p53, by preventing the activation of cyclin B1/CDC2 complexes.

CDKN2A also binds to:
• BCL6, downregulating BCL6-induced transcriptional repression;
• E2F1 and MYC, blocking their transcriptional activator activity;
• HUWE1, repressing its ubiquitin ligase activity;
• TOP1/TOPOI, stimulating its activity. This complex binds to rRNA gene promoters and may play a role in rRNA transcription and/or maturation.

CDKN2A interacts with:
• COMMD1 and promotes its “Lys63”-linked polyubiquitination;
• NPM1/B23, promoting its polyubiquitination and degradation and inhibiting rRNA processing;
• UBE2I/UBC9, enhacing sumoylation of some of its binding partners (e.g., MDM2 and E2F1).
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
References in periodicals archive ?
To our knowledge, the T2D association of rs7578326 (IRS1), rs1531343 (HMGA2), rs8042680 (PRC1), rs1387153 (MTNR1B), rs7578597 (THADA) [25], rs243021 (BCL11A) [26], and rs1333051 (CDKN2) [27] was replicated in an East Asian sample for the first time.
Mutational analysis of Cdkn2 (Mts/[P16.sup.ink4]) in human breast carcinomas.
Involvement of the p16INK4 (CDKN2) gene in familial melanoma.
Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma.
P16 (CDKN2) is a major deletion target at 9p21 in bladder cancer.
Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.